NICE rejects Erbitux in head and neck cancer

pharmafile | June 24, 2009 | News story | Research and Development, Sales and Marketing |  Erbitux, Merck Serono, NICE 

Related Content

NICE backs atogepant for acute migraine treatment

NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the …

NICE recommends sotatercept for pulmonary arterial hypertension

The National Institute for Health and Care Excellence (NICE) has recommended Winrevair (sotatercept) as a …

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …

The Gateway to Local Adoption Series

Latest content